BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 23199022)

  • 21. Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis.
    Ayuso C; Forner A; Darnell A; Rimola J; García-Criado Á; Bianchi L; Vilana R; Oliveira R; Llarch N; Bruix J
    Liver Int; 2019 Jul; 39(7):1281-1291. PubMed ID: 31077539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria.
    Leoni S; Piscaglia F; Golfieri R; Camaggi V; Vidili G; Pini P; Bolondi L
    Am J Gastroenterol; 2010 Mar; 105(3):599-609. PubMed ID: 19935786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.
    Ahn SS; Kim MJ; Lim JS; Hong HS; Chung YE; Choi JY
    Radiology; 2010 May; 255(2):459-66. PubMed ID: 20413759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between areas with Gd-EOB-DTPA uptake and without in hepatocellular carcinomas on Gd-EOB-DTPA-enhanced hepatobiliary-phase MR imaging: pathological correlation.
    Lee S; Kim SH; Park CK; Kim YS; Lee WJ; Lim HK
    J Magn Reson Imaging; 2010 Sep; 32(3):719-25. PubMed ID: 20815073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological significance of the peritumoral decreased uptake area of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid in hepatocellular carcinoma.
    Nishie A; Asayama Y; Ishigami K; Kakihara D; Nakayama T; Ushijima Y; Takayama Y; Shirabe K; Fujita N; Kubo Y; Hirakawa M; Honda H
    J Gastroenterol Hepatol; 2014 Mar; 29(3):561-7. PubMed ID: 24219648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primovist, Eovist: what to expect?
    Van Beers BE; Pastor CM; Hussain HK
    J Hepatol; 2012 Aug; 57(2):421-9. PubMed ID: 22504332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers.
    Bartolozzi C; Battaglia V; Bargellini I; Bozzi E; Campani D; Pollina LE; Filipponi F
    Abdom Imaging; 2013 Apr; 38(2):290-6. PubMed ID: 23053453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypointense hepatocellular nodules on hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI: can increasing the flip angle improve conspicuity of lesions?
    Tamada T; Ito K; Yamamoto A; Yasokawa K; Higaki A; Kanki A; Sato T; Tanimoto D; Higashi H
    J Magn Reson Imaging; 2013 May; 37(5):1093-9. PubMed ID: 23148032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production.
    Asayama Y; Tajima T; Nishie A; Ishigami K; Kakihara D; Nakayama T; Okamoto D; Fujita N; Aishima S; Shirabe K; Honda H
    Eur J Radiol; 2011 Dec; 80(3):e243-8. PubMed ID: 21109378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.
    Toyoda H; Kumada T; Tada T; Sone Y; Maeda A; Kaneoka Y
    Hepatol Int; 2015 Jan; 9(1):84-92. PubMed ID: 25788383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images.
    Wang YC; Chou CT; Lin CP; Chen YL; Chen YF; Chen RC
    PLoS One; 2017; 12(3):e0174594. PubMed ID: 28355258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?
    Bashir MR; Gupta RT; Davenport MS; Allen BC; Jaffe TA; Ho LM; Boll DT; Merkle EM
    J Magn Reson Imaging; 2013 Feb; 37(2):398-406. PubMed ID: 23011874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of diffusion-weighted imaging and gadoxetic acid-enhanced MR images in the evaluation of hepatocellular carcinoma and hypovascular hepatocellular nodules.
    Di Pietropaolo M; Briani C; Federici GF; Marignani M; Begini P; Delle Fave G; Iannicelli E
    Clin Imaging; 2015; 39(3):468-75. PubMed ID: 25748089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using Gd-EOB-DTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis.
    Park YS; Lee CH; Kim BH; Lee J; Choi JW; Kim KA; Ahn JH; Park CM
    Magn Reson Imaging; 2013 Sep; 31(7):1137-42. PubMed ID: 23688409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma.
    Ariizumi S; Kitagawa K; Kotera Y; Takahashi Y; Katagiri S; Kuwatsuru R; Yamamoto M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):575-85. PubMed ID: 21360083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.
    Motosugi U; Bannas P; Sano K; Reeder SB
    J Magn Reson Imaging; 2015 Feb; 41(2):251-65. PubMed ID: 25104398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnosis of hypovascular hepatic lesions showing hypo-intensity in the hepatobiliary phase of Gd-EOB- DTPA-enhanced MR imaging in high-risk patients for hepatocellular carcinoma.
    Nakamura S; Nouso K; Kobayashi Y; Shiraha H; Ohnishi H; Toshimori J; Kuwaki K; Hagihara H; Takayama H; Yamamoto K
    Acta Med Okayama; 2013; 67(4):239-44. PubMed ID: 23970322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.